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ABSTRACT 
The purpose of the present investigation was to study the aerosolization, lungs deposition and pharmacokinetic 
study of inhalable submicron particles of budesonide in male Wistar rats. Submicron particles were prepared by 
antisolvent nanoprecipitation method and freeze-dried to obtain free flowing powder. The freeze-drying process 
yielded dry powder with desirable aerodynamic properties for inhalation therapy. An in-house model inhaler was 
designed to deliver medicine to lungs, optimized at dose level of 10 mg for 30 sec of fluidization. The in vitro 
aerosolization study demonstrates that submicron particles dissolve faster with improved aerosolization effect as 
compared to micronized budesonide. Both submicron and micron particles were compared for in vivo lungs dep-
osition. The results showed that relatively high quantity of submicron particles reaches deep into the lungs as 
compared to micron particles. Most pronounced effect observed with submicron particles from pharmacokinetic 
parameters was the enhancement in peak plasma concentration (Cmax) by 28.85 %, and increase in area under 
concentration curve (AUC0–8h) by 30.33 % compared to micron sized particles. The results suggested that devel-
oped submicronized formulation of budesonide can be used for pulmonary drug delivery for high deposition to 
deep lungs tissues.  
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INTRODUCTION 
Inhaled corticosteroids (ICSs) are effec-
tive in chronic inflammation associated with 
asthma, reported to improve pulmonary func-
tion and are recommended as first-line ther-
apy for asthmatic patients (Pornputtapitak et 
al., 2014). There is considerable evidence that 
treatment with anti-inflammatory ICSs re-
duces morbidity and mortality in asthma 
(Stoloff et al., 2004). ICSs appeared to have a 
place in the management of severe chronic 
obstructive pulmonary disease (COPD), per-
haps by reducing the frequency of exacerba-
tion and improvement in their quality of life 
(Chou and D’Urzo, 2014). 
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In recent years, pulmonary dosage forms 
have established an important role in local-
ized treatment of lungs diseases. Systemic de-
livery through the lungs is also emerging as 
an alternate route due to richly blood perfused 
surface area, avoidance of first-pass metabo-
lism, and reduces drug degradation that may 
occur in the gastrointestinal tract (Foster et 
al., 2001; Rasenack et al., 2003). Pulmonary 
drug delivery approaches continue to develop 
rapidly in an effort to improve product stabil-
ity and efficacy for local and systemic treat-
ment of diseases (Chougule et al., 2007). The 
main problem with pulmonary drug delivery 
is the poor deposition efficiency. In some 
cases only 10 % of the inhaled drug powder 
reaches the alveoli (Chougule et al., 2007).  
In addition, many current and emerging 
formulations would benefit from improved 
drug dissolution rate, which often enhances 
drug bioavailability. In the past, significant 
efforts have been dedicated to expand nano-
technology for drug delivery since it offers a 
potential means of improving the delivery of 
small molecule drugs as well as macromole-
cules such as proteins, peptides, or genes to 
the tissues of interest (Umeyor et al., 2001; 
Bateman et al., 2008). Increase in the percent-
age of poorly water-soluble molecules being 
identified as active pharmaceutical ingredi-
ents beckons new approaches to bring these 
molecules to the market place in a timely 
fashion (Merisko-Liversidge et al., 2003). Na-
noparticle suspension used in nebulizers or 
metered dose inhalers often suffers from 
physical instability in the form of uncon-
trolled agglomeration or Ostwald ripening. In 
addition, processing of such suspensions into 
dry powders can yield broad particle size dis-
tributions (El-Gendy et al., 2009). There are 
many advantages for developing dry powder 
inhalable (DPI) formulations for pulmonary 
drug delivery, which include reduced dosing 
frequency, improved patient compliance and 
reduction of side effects (Roche and Huchon, 
2005). 
Budesonide (BUD), an inhaled cortico-
steroid (ICS), is one of the most valuable ther-
apeutic agents for the prophylactic treatment 
of moderate to severe asthma. Budesonide is 
reported to have high ratio of topical anti-in-
flammatory to systemic activity and is one of 
the most extensively used inhaled corticoster-
oid (Roche and Huchon, 2005; Daley‐Yates, 
2015). Budesonide also decreases airway hy-
per-responsiveness and reduces the number of 
inflammatory cells and mediators present in 
the airways of patients with asthma. ICS reach 
their site of action and the receptor by diffus-
ing into the cells. Therefore, a fast dissolution 
of the drug molecule in the lungs is desired. 
The advantages of submicron drug particles 
are due to their increased solubility and disso-
lution as compared to micron particles, there-
fore improving the inhalable properties. The 
higher saturation solubility and increased dis-
solution velocity can be explained by the Kel-
vin-Ostwald-Freundlich and Noyes-Whitney-
Prandtl equations (Ali et al., 2016). Adhesive-
ness of small particles onto the surface of site 
of action and increase in bioavailability are 
also among the advantages of submicron par-
ticles. 
It is well known from powder technology 
that fine powders/particles generally possess 
an increased adhesiveness to surfaces com-
pared to larger one. Also, tendency of the par-
ticles to stick on mucosal surface at the ab-
sorption site enhances absorption rate 
(Junyaprasert and Morakul, 2015). A pro-
longed residence time at the site of absorption 
would be still beneficial, because microparti-
cles are transported out from the lungs by cilia 
movement, whereas small particles at nano 
scale adhere a longer time onto the mucosal 
surface and in that way the submicron parti-
cles can be used to increase the absorption of 
budesonide (Jacobs and Muller, 2002). Sub-
micronized particles generally contain a very 
low or no fraction of microparticles, which re-
duces unwanted deposition of particles in 
mouth and pharynx, therefore decreases local 
side effects. On the basis of these known prin-
ciples, the advantages of submicron drug par-
ticles are used to improve drug formulations 
for pulmonary delivery of budesonide. Sub-
micron drug particles can be obtained by dif-
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ferent production methods. If the drug is sol-
uble in an organic solvent, precipitation 
would be a possible method (Gao et al., 
2008).  
For the present study, submicron drug 
particles were prepared by nanoprecipitation 
method. The main objective of the study was 
to investigate the aerosolization effect of de-
veloped submicron particle and also to carry 
out lungs deposition and pharmacokinetic 
study in male Wistar rats.  
 
MATERIALS AND METHODS 
Materials 
Micronized budesonide was a generous 
gift from Lupin India Ltd. (Pune, India). 
Leutrol F68 was obtained from BASF Co. 
(Mumbai, India). Different grades of inhala-
ble lactose, mannitol and sorbitol were pro-
cured from DFE pharmaceuticals (Bangalore, 
India).  All other chemicals and reagents were 
of analytical grade and used as received with-
out further purification. 
 
Methods 
Preparation of submicronized DPI  
formulation 
1 % budesonide solution was prepared by 
dissolving in a mixture of organic solvent [ac-
etone: ethanol (3:1 ratio)] and added to deion-
ized water previously mixed with 0.5 % 
leutrol F68 dropwise with constant stirring at 
1200 rpm for 2.5 hrs. Solvent to antisolvent 
ration was 0.2. After complete evaporation of 
organic solvent, submicronized suspension 
was subjected to high pressure homogeniza-
tion (600 bar/3 cycles) to obtain desired parti-
cle size. Dry powder formulation was ob-
tained by freeze-drying process using a mix-
ture of cryoprotectant (drug: lactose: sorbitol: 
mannitol: 1: 25: 5: 15). Conventional mi-
cronized DPI formulation was prepared 
simply by blending micronized budesonide 
with lactose to yield free flowing inhalable 
powder. 10 mg of dry powder formulation 
was equivalent to 200 µg of budesonide. 
Aerosolization study 
Aerosolization study was performed in 
the climate chamber (25 °C/65 % RH) using 
Andersen cascade impactor (ACI). Formula-
tion equivalent to 200 µg of budesonide was 
released into the ACI consisting of a throat, a 
preseparator, 8 frames with non-coated plates, 
a filter connected to a 3-way valve and a vac-
uum pump (air flow 60 l/min; flow time 
8 sec). The budesonide deposited onto each 
frame and plate, throat, preseparator and filter 
was dissolved in 50 ml mobile phase (metha-
nol: water; 90:10 %v/v), and the concentra-
tion was analyzed using validated HPLC 
method. The total recovered mass (RM) and 
the total fine particle mass (FPM) (≤ 5.8 µm) 
of emitted budesonide were calculated. The 
respirable fraction (RF) was calculated using 
the equation; 
 
%	Respirable	fraction	ሺRFሻ 	
ൌ ܶ݋ݐ݈ܽ	ܨ݅݊݁	ܲܽݎݐ݈݅ܿ݁	ܯܽݏݏ	ሺܨܲܯሻܴ݁ܿ݋ݒ݁ݎ݁݀	ܯܽݏݏ	ሺܴܯሻ 	
ൈ 100 
The mass median aerodynamic diameter 
(MMAD) is the median value of a curve rep-
resenting the cumulative particle size distri-
bution. 
Fabrication and working of in-house model 
inhaler  
In order to deliver submicronized DPI for-
mulation to investigational rodents, an inhala-
tion apparatus (Figure 1) was engineered and 
patented (Jamia Hamdard University; 2012. 
Indian Patent: 1731/DEL/2010). The condi-
tions were optimized for better delivery by 
conducting preliminary trials based on loaded 
amount and fluidization time. In brief, the flu-
idizing chamber consists of 15 mL glass tube 
having an even hole about 0.5 cm in diameter 
on its wall at a distance of about 2.5 cm from 
the tip. A fine glass tubing of 2 mm internal 
diameter was inserted into the fluidizing 
chamber from the top of the taper to clearance 
of about 2.5-5 cm from the cap’s inner sur-
face. It also consists of two holes at the top of 
fluidizing chamber with 0.1 mm diameter 
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plugged with cotton wool to counter balance 
the sudden rise in pressure inside the cham-
ber. The glass tubing was connected to a 
pumping bulb through a plastic tube.  
 
 
Figure 1: Schematic representation of different 
parts of in-house model inhaler 
 
 
The plastic tube consists of a junction 
which controls the unidirectional air flow to 
prevent drug powder sucked off by vacuum 
created during relaxation of pumping bulb. 
The pumping bulb was manually triggered to 
fluidize the bed of the respective DPI formu-
lation. Complete dispersion of powder bed 
was achieved with very low volumes of high 
velocity air coming out of the inlet end of 
glass tubing to form the desired aerosol. Pre-
weighted sample for inhalation were gently 
put in the central drug loading template 
placed at cap, which acts as a receptacle and 
thereafter fastened (screw tight) to the body.  
The sterile cotton wool plug (200 mg in 
weight) was held over the outer orifice of the 
fluidizing chamber. The dose fluidized from 
the in-house inhalation apparatus under com-
parable conditions of airflow was determined 
by collecting submicronized and micronized 
DPI formulation on cotton plug held at deliv-
ery outlet when the apparatus was actuated 
with different amount of sample loaded on the 
drug loading template. For the system valida-
tion, the fabricated apparatus was primed with 
respective budesonide dry powder formula-
tion by fluidizing five doses and discarded the 
residue. This procedure led to adsorption of 
significant amount of DPI on the wall of the 
apparatus, and increased the amount as well 
as the reproducibility of dose delivered as 
compared to unprimed apparatus. 
 
Optimization of dose delivery  
After priming of apparatus, the scheme of 
fluidization was studied between 10-40 sec 
using different amount of DPI formulations 
(5-20 mg) to ensure optimum exposure. The 
rubber bulb of apparatus was actuated with 
the pressure at the rate of 1 actuation/sec. A 
sheaf of cotton wool was used to completely 
occlude the delivery port to observe the quan-
tity available for animal at mouth piece region 
during exposure. The sheaf surface exposed 
to fluidized DPI formulations remained flush 
with the inner wall of the tube and the area of 
the sheaf exposed to aerosol was quite same 
in each determination. Finally, the powder 
laden cotton wool plug was extracted for 
budesonide in mobile phase and analyzed by 
validated HPLC method.  
 
In vivo lungs deposition and  
pharmacokinetic study 
DPI exposure to animals 
Authorization to conduct in vivo study 
was obtained from Institutional Animal Eth-
ics Committee, B. N. College of Pharmacy 
(Reg. No. 870/ac/08/CPCSEA). Male Wistar 
rats (200-250 g) were provided by the experi-
mental central animal house. The animals 
were kept under standard laboratory condi-
tions at 25 ± 2 °C temperature and 60 ± 5 % 
relative humidity, housed in polypropylene 
cages, with free access to standard laboratory 
diet (Lipton feed, Mumbai, India) and water 
ad libitum. A period of 7 days was allowed for 
acclimatization of rats before any experi-
mental manipulation was undertaken. The rats 
were fasted overnight before the day of the 
experiment. After priming of apparatus, the 
drug loading template of fluidizing chamber 
was loaded with 10 mg (equivalent to 200 µg 
budesonide) sample of dry powder and the 
cap was fastened to the body. Rats were re-
strained with their snout placed against the 
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peripheral aperture of the apparatus and the 
pumping bulb was gently actuated to fluidize 
the sample at the rate of 1 actuation/sec.  
Collection of blood samples and tissues 
Samples of blood were collected by the 
method reported in the literature (Shirasaki et 
al., 2012) with slight modification. Rats were 
held by grasping the loose skin of the back 
firmly with fingers and head elevated without 
spreading the submaxillary gland. Petroleum 
jelly was applied to fur previously wetted 
with alcohol, revealing the jugular vein as a 
blue pulsating area. 27 gauge needles were in-
serted into the jugular vein through the pecto-
ral muscle below the sternoclavicular junction 
and 0.5 mL blood was collected at scheduled 
time point (0.5 min - 8 hrs). Animals were 
anesthetized by an intraperitoneal injection of 
xylazine (5 mg/kg) combined with ketamine 
HCl (50 mg/kg). Tissues removed after dis-
section was treated with phosphate buffer sa-
line (pH 7.4) to remove unwanted residue. 
Drug particulates deposited in nasal cavity 
and on facial hairs were separately collected 
by washing with 10 mL acetonitrile solution.  
Plasma sample preparation  
Collected blood samples were transferred 
in EDTA-coated microcentrifuge tubes, cen-
trifuged at 10,000 rpm for 10 min. Plasma 
separated was stored at -21 °C until drug anal-
ysis. After thawing plasma samples were 
mixed with 4 % phosphoric acid solution in 
1:1 ratio to release protein-bound drugs 
(Vieira et al., 2010). The samples were ex-
tracted with 3 mL of ethyl acetate. The or-
ganic phase was separated by centrifugation 
at 3,000 rpm for 10 min and evaporated to 
dryness over a stream of nitrogen gas. The 
residue was reconstituted with 0.1 mL of mo-
bile phase (methanol: water; 90: 10 %v/v), 
and analyzed by validated HPLC method.   
Pharmacokinetic parameters were calcu-
lated by noncompartmental analysis also 
called as Model independent analysis using 
WinNonLin version 4.0 (Pharsight Corp., 
Mountain View, CA). Maximum plasma con-
centration (Cmax), time to reach maximum 
plasma concentration (Tmax), area under the 
concentration curve from 0–8 hrs (AUC0–8), 
area under the concentration curve for 0 to in-
finity (AUC0–∞), and mean residence time 
(MRT) were calculated.  
Extraction of drug from tissues 
Tissues were homogenized in water 
(1 mL/g) using a Potter S Homogenizer (B. 
Braun Biotech International, Melsungen, 
Germany). Tissue homogenates were shaken 
in a mechanical shaker for 3 min previously 
mixed with 10 mL acetonitrile and exten-
sively centrifuged at 4000 rpm for 10 min. Su-
pernatant solution was collected separately in 
a glass tube and liquid–liquid extraction was 
performed by rolling for 10 min with ether 
(Lin et al., 2015). After centrifugation the or-
ganic layer was transferred into a new tube 
and evaporated until dry under oxygen free 
nitrogen (OFN) at 40 °C. The samples were 
reconstituted with 5 mL mobile phase (meth-
anol: water; 90: 10 %v/v). 10 µL samples 
were injected and analyzed by the validated 
HPLC method. Budesonide content was de-
termined by using regression analysis equa-
tion. Aliquots obtained by washing of nasal 
cavity and on facial hairs were also separately 
collected, extracted and analyzed similarly. 
 
HPLC condition 
The apparatus consisted of Shimadzu 
(Kyoto, Japan) liquid chromatography 
equipped with an LC-10ADVP pump and an 
SPD-10AVP UV detector. Chromatographic 
separations were performed on a Phenomenex 
reverse phase C-18 (250 x 4.6 mm, 5 µm) 
Luna column, coupled with a C18 guard col-
umn. Data was analyzed using Shimadzu 
CLASS-VP software (Version 6.2). The 
budesonide peak was eluted at approximately 
4.30 min, at a flow rate of 1 mL/min, injection 
volume of 10 µL, and absorption wavelength 
of 240 nm.  
 
RESULTS AND DISCUSSION 
Aerosolization study 
The fine particle dosage (< 5.5 microns) 
for submicronized DPI formulation, conven-
tional micronized formulation and pure drug 
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were found to be 82.36 %, 60.87 % and 
36.72 %, respectively (Table 1). The respira-
ble dose (< 3.3 microns) for submicronized 
formulation was 69.04 %, which was 2.16 
times higher than conventional micronized 
formulation and 4.9 times higher than pure 
drug. The emitted dose of each formulation 
was considered as 100 % for in vitro deposi-
tion study. The mass median aerodynamic di-
ameter (MMAD) were smallest (1.59) com-
pared to other samples, which advocates sig-
nificant improvement in in vitro drug deposi-
tion for submicronized formulation. 
 
Optimization of dose delivery  
The inhalation apparatus assembly was 
designed to facilitate maximum exposure of 
fluidized formulation as well as collection of 
formulation over cotton wool plug in minimal 
time. The amount of budesonide collected on 
the cotton wool plugs are presented in Table 
2. The optimal condition to deliver ~200 µg 
budesonide dose was found to be 30 sec and 
40 sec (Rate of actuation: 1 actuation/sec) for 
submicronized and micronized DPI formula-
tion, respectively. Additionally, this method 
can be used to examine the behaviour of inha-
lation dosage form with different aerody-
namic particle distribution and the amount of 
dry powder dose. 
 
In vivo lungs deposition study  
After inhalation of submicronized and mi-
cronized DPI formulation, the content of 
budesonide deposited at different biometrics 
of Wistar rats respiratory tract were analyzed 
(Table 3, Figure 2). Average content depos-
ited on to the lungs, trachea, nasal cavity and 
facial hairs was 85.70 µg, 34.32 µg, 19.36 µg 
and 31.70 µg of budesonide, respectively for 
submicronized DPI formulation. Whereas for 
micronized DPI formulation, the average con-
tent deposited was 48.49 µg, 57.86 µg, 28.83 
µg and 41.10 µg, respectively. In general, 
85.54 % and 88.14 % were assayed for sub-
micronized and micronized DPI formulation, 
respectively after actuation of 10 mg dose 
(equivalent to 200 µg budesonide). 
 
 
 
Table 1:In vitro lungs deposition of micronized and submicronized DPI formulation using Andersen 
cascade impactor (ACI) 
Particle size range % drug deposited ± SD 
Pure BUD Micronized DPI  
Formulation 
Submicronized DPI 
Formulation 
Device 28.18 ± 2.26 14.96 ± 1.75 12.42 ± 1.91 
Emitted Dose 71.82 ± 2.26 85.04 ± 1.75 87.68 ± 1.91 
Throat 35.25 ± 1.37 22.41 ± 1.51 10.76 ± 1.56 
9.0–10.0 µm (µg)—Stage 0 19.64 ± 1.19 5.12 ± 1.09 1.68 ± 0.67 
5.8-9.0 µm (µg)—Stage 1 13.17 ± 2.15 9.59 ± 1.24 2.38 ± 0.96 
4.7–5.8 µm (µg)—Stage 2 12.23 ± 2.35 13.23 ± 2.17 4.79 ± 1.45 
3.3–4.7 µm (µg)—Stage 3 10.35 ± 1.14 15.73 ± 1.45 8.53 ± 1.29 
2.1–3.3 µm (µg)—Stage 4 8.24 ± 1.22 12.16 ± 1.68 13.14 ± 1.3 
1.1–2.1 µm (µg)—Stage 5 4.5 ± 1.43 10.8 ± 0.91 32.2 ± 2.1 
0.65–1.1 µm (µg)—Stage 6 1.4 ±.95 6.22 ± 0.56 19.24 ± 1.3 
0.43–0.65 µm (µg)—Stage 7 0 2.73 ± 0.44 3.76 ± 0.58 
0-0.43 µm (µg)—Filter 0 0 0.7 ± 0.2 
FPD (< 5.5) 36.72 ± 3.12 60.87 ± 2.57 82.36 ± 2.19 
RD (< 3.3) 14.14 ± 1.20 31.91 ± 2.75 69.04 ± 2.34 
MMAD 6.11 ± 1.40 3.67±  0.68 1.59 ± 0.14 
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Table 2: Optimization of dose delivered from in-house model inhaler 
Amount of DPI formulation  
loaded (mg) 
Amount of drug collected on cotton wool (µg) 
Submicronized DPI Formulation 
10 Sec 20 sec 30 sec 40 sec 
5 46.4 ± 3.46 97 ± 4.29 98.8 ± 5.73 99 ± 3.79 
10 59.4 ± 5.10 156.6 ± 6.12 198.2 ± 4.83 198.8 ± 3.11 
15 92.2 ± 9.76 195.8 ± 12.21 244.4 ± 8.46 296.6 ± 12.46 
20 133.8 ± 10.23 217.6 ± 17.46 293 ± 21.46 351.4 ± 17.46 
Amount of DPI formulation  
loaded (mg) Micronized DPI Formulation 
10 Sec 20 sec 30 sec 40 sec 
5 41.7 ± 4.11 88 ± 3.27 94.4 ± 4.21 99.1 ± 2.41 
10 52.2 ± 7.3 129 ± 8.23 185.6 ± 5.71 199.5 ± 5.25 
15 84.7 ± 11.12 179.9 ± 14.82 238.4 ± 7.20 288.2 ± 14.38 
20 118.2 ± 12.33 205.8 ± 16.37 287 ± 17.51 348.8 ± 14.91 
 
 
 
Table 3: Content deposited at different biometrics after inhalation to Wistar rats (n=3). 
Biometrics Submicronized DPI Formulation Micronized DPI Formulation 
Total content 
(µg) 
Content (%) Total content (µg) Content (%) 
Lungs  85.70 ± 4.82 42.85 ± 2.24 48.49 ± 3.73 24.25 ± 2.52 
Trachea  34.32 ± 2.83 17.16 ± 3.27 57.86 ± 3.68 28.93 ± 2.51 
Nasal cavity wash residue 19.36 ± 2.91 9.68 ± 1.32 28.83 ± 1.82 14.41 ± 0.95 
Facial hair wash residue 31.70 ± 1.43 15.85 ± 1.42 41.10 ± 2.38 20.55 ± 2.53 
 
 
Figure 2: Drug deposited at different biometrics after inhalation to Wistar rats 
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Pharmacokinetic study 
The mean budesonide plasma concentra-
tion–time profiles are illustrated in Figure 3. 
Estimated pharmacokinetic parameters of 
budesonide are listed in Table 4. Observed 
peak plasma concentration (Cmax) of submi-
cronized and micronized DPI formulation 
were 588.17 ± 97.5 ng/ml and 456.47 ± 102.4 
ng/ml, respectively and the time to reach peak 
plasma concentration (Tmax) were 0.25 h for 
both the formulations. Cmax for submicronized 
formulation was found to be significantly 
higher than conventional micronized formu-
lation (p < 0.01). The overall area under con-
centration curve (AUC0–8h) for submicronized 
and micronized formulation were found to be 
1989.28 ± 242.8 ng h/ml and 1527.53 ± 222.3 
ng h/mL, respectively. Thus, a significantly 
higher AUC was observed for submicronized 
DPI formulation compared to micronized for-
mulation (p < 0.01). The high value of Cmax 
and AUC ensured higher drug availability at 
the site of action. In general, inhalation expo-
sure resulted in due effect of submicronized 
DPI formulation by initial burst effect fol-
lowed by rapid drug released. 
The difference in the values of MRT0-∞ 
was not significant (p > 0.05) when the sub-
micronized and micronized formulation was 
compared, as there is no change in the intrin-
sic properties of the drug when it was formu-
lated into micronized and submicronized 
forms. 
 
Figure 3: Plasma concentration profile of budesonide after inhalational administration of submicronized 
and micronized DPI formulation in Wistar rats (n=3). Data represents the mean ± SD (n = 3). 
 
 
Table 4: Pharmacokinetic profile of budesonide in Wistar rats (n=3) after inhalational administration 
Parameters Submicronized DPI formulation Micronized DPI formulation
Cmax a (ng/ml) 588.17* ± 97.5 456.47 ± 102.4 
Tmaxb (h) 0.25 ± 0.04 0.25 ± 0.06 
AUC0–tc(ng h /ml) 1989.28* ± 242.8 1527.53 ± 222.3 
AUC0-∞d (ng h /ml) 2220.14 *± 320.4 1737.96 ± 193.7 
MRT0-te (h) 3.62** ± 0.23 3.78 ± 0.25 
*p < 0.01 and **p > 0.05 when compared with micronized formulation using one way ANOVA followed by Tukey–Kramer multiple 
comparison test. a Peak of maximum concentration; b Time of peak concentration; c Area under the concentration time profile curve 
until last observation; d Area under curve extrapolated to infinity; e Mean residence time 
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CONCLUSION 
The study presents successful develop-
ment of submicronized DPI formulation of 
budesonide and their application as a drug 
carrier in pulmonary delivery to the lungs. Re-
sults of in vitro aerosolization study depicted 
better effect of submicron particles compared 
to micronized particles. In vivo lungs deposi-
tion study advocated that the submicronized 
formulation has high and deep lungs deposi-
tion of budesonide. The high value of Cmax 
and AUC ensured higher drug availability at 
the site of action. Therefore, the formulation 
holds a great potential for treating diseases 
that require direct lungs delivery with reduced 
dosage and dosing frequency, leading to 
fewer systemic side effects and improved pa-
tient compliance. 
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